GlassScriptPhysician profile
Manuel A Gomez
NPI 1952487688
$859.68
in general payments reported to CMS, 2019-2025
10 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2023: $49.89 · 2024: $443 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $252.73 | 2019-2024 | Arexvy |
| Amgen INC. | $121.84 | 2024 | Repatha |
| Lilly USA, LLC | $108.38 | 2025 | Zepbound |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $86.94 | 2024 | Airsupra |
| Abiomed | $52.94 | 2024 | Impella |
| Novo Nordisk INC | $49.89 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2024 | |
| Pfizer INC. | $27.56 | 2024 | |
| Supernus Pharmaceuticals, INC. | $24.55 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.